EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors

Daniele Musiani, Hatice Yücel, Marie Vallette, Annapaola Angrisani, Rania El Botty, Bérengère Ouine, Niccolo Schintu, Caroline Adams, Manon Chevalier, Derrien Heloise, Ahmed El Marjou, Ivan Nemazanyy und 4 weitere

Molecular Cell · 2025

DOI: 10.1016/j.molcel.2025.01.031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Cell, 2025. Verfasst von Daniele Musiani und 15 weiteren Autor:innen. Beteiligte Einrichtung: INSERM U830, PSL Research University, Institut Curie, Paris, France. Hauptthemen laut MEDLINE: Uracil-DNA Glycosidase, BRCA1 Protein, Uracil, BRCA2 Protein. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Horizon 2020 Framework Programme, European Research Council, Dana-Farber Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) is the major obstacle to their effectiveness in the treatment of homologous recombination (HR)-deficient (HRD) tumors. Hence, developing alternative treatments for HRD tumors is critical. Here, we show that targeting the uracil excision pathway kills HRD tumors, including those with PARPi resistance. We found that the interplay between the two major uracil DNA glycosylases UNG and SMUG1 is regulated by nuclear nicotinamide adenine dinucleotide (NAD+), which maintains UNG at replication forks (RFs) and restrains SMUG1 chromatin binding. In the absence of UNG, SMUG1 retention on chromatin leads to persistent abasic sites, which incision by APE1 results in PARP1 hyperactivation, stalled RFs, and RAD51 foci. In HRD cells (i.e., BRCA1/2-deficient), this leads to under-replicated DNA that, when propagated throughout mitosis, results in chromosome fragmentation and cell death. Our findings open up unique possibilities for targeted therapies for HRD tumors based on UNG inhibition and uracil accumulation in the genome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uracil-DNA GlycosidaseBRCA1 ProteinUracilBRCA2 ProteinHomologous RecombinationHumansAnimalsPoly(ADP-ribose) Polymerase InhibitorsCell Line, TumorFemaleMiceNADPoly (ADP-Ribose) Polymerase-1ChromatinDrug Resistance, NeoplasmRad51 RecombinaseDNA Replication

Stichwörter der Autor:innen

HR-deficient breast and ovarian tumorsPARP1 hyperactivationPARPi resistanceSMUG1/UNG crosstalkdUTP DNA incorporationgenomic instabilitynuclear NAD(+)replication stresssynthetic lethalityuracil excision repair

Substanzen

Uracil-DNA GlycosidaseBRCA1 ProteinUracilBRCA2 ProteinBRCA1 protein, humanSMUG1 protein, humanBRCA2 protein, humanPoly(ADP-ribose) Polymerase InhibitorsNADPoly (ADP-Ribose) Polymerase-1

Autor:innen und Institutionen

  • INSERM U830, PSL Research University, Institut Curie, Paris, France.
  • Institut Curie, PSL Research University, Sorbonne Université, CNRS, UMR144 and UMR3664, 26 rue d'Ulm, 75005 Paris, France.
  • Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL Research University, Paris, France.
  • Recombinant Protein Facility CNRS UMR144, Institut Curie, PSL Research University, Paris, France.
  • Platform for Metabolic Analyses, Structure Fédérative de Recherche Necker, INSERM US24/CNRS UAR 3633, Paris, France.
  • INSERM U830, PSL Research University, Institut Curie, Paris, France; Laboratoire de Biologie et Pharmacologie Appliquée, ENS-Paris-Saclay, CNRS UMR 8113, Université Paris-Saclay, 91190 Gif-sur-Yvette, France.

Förderung

  • Horizon 2020 Framework Programme
  • European Research Council
  • Dana-Farber Cancer Institute
  • Fondation de France
  • School of Medicine, Tokai University
  • Horizon 2020
  • Istituto Europeo di Oncologia
  • Institut Curie

Zitieren

APA

Musiani, D., Yücel, H., Vallette, M., Angrisani, A., El Botty, R., Ouine, B., Schintu, N., Adams, C., Chevalier, M., Heloise, D., El Marjou, A., Nemazanyy, I., Regairaz, M., Marangoni, E., Fachinetti, D., & Ceccaldi, R. (2025). Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors. Molecular Cell. https://doi.org/10.1016/j.molcel.2025.01.031

Vancouver

Musiani D, Yücel H, Vallette M, Angrisani A, El Botty R, Ouine B, et al. Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors. Molecular Cell. 2025. doi:10.1016/j.molcel.2025.01.031

BibTeX
@article{Musiani2025,
  author = {Musiani, Daniele and Yücel, Hatice and Vallette, Marie and Angrisani, Annapaola and El Botty, Rania and Ouine, Bérengère and Schintu, Niccolo and Adams, Caroline and Chevalier, Manon and Heloise, Derrien and El Marjou, Ahmed and Nemazanyy, Ivan and Regairaz, Marie and Marangoni, Elisabetta and Fachinetti, Daniele and Ceccaldi, Raphael},
  title = {Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors},
  journal = {Molecular Cell},
  year = {2025},
  doi = {10.1016/j.molcel.2025.01.031}
}
Kostenlos starten →